Maxcyte vs Rapid Micro Biosystems
Maxcyte and Rapid Micro Biosystems are similar in size: $33.0m and $33.6m of revenue in their latest fiscal years. Rapid Micro Biosystems grew faster (19.7% against -14.5%). Maxcyte kept more of each dollar of sales as profit: a net margin of -135.1% against -140.3%.
| Latest fiscal year | MaxcyteMXCT, 2025 | Rapid Micro BiosystemsRPID, 2025 |
|---|---|---|
| Revenue | $33.0m | $33.6m |
| Revenue growth | -14.5% | 19.7% |
| Net income | −$44.6m | −$47.1m |
| Operating margin | -157.1% | — |
| Net margin | -135.1% | -140.3% |
| Return on equity | -23.6% | -86.8% |
| Free cash flow | −$36.2m | −$31.9m |
| Cash | $20.1m | $20.0m |
| Total debt | $0 | $18.9m |
| Debt to equity | 0.0% | — |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 91 | 171 |
| Market value | $154m | $34.0m |
| Price vs our value range | — | — |
| Moat score | 30 (Weak) | 12 (Weak) |
| Insider trades, 12 months | 0 buys, 1 sales | 0 buys, 14 sales |